Clinical Recruitment | Subject Recruitment for Use of Almonertinib in Treatment of Non-Progressive NSCLC after Radical Platinum-Containing Chemoradiotherapy
The "Randomized, Controlled, Double-Blind and Phase III Clinical Study of Almonertinib Mesilate VS Placebo in Maintenance Treatment of NSCLC Patients ...
2021.03.30